Journal
BIOPOLYMERS
Volume 102, Issue 3, Pages 280-287Publisher
WILEY-BLACKWELL
DOI: 10.1002/bip.22488
Keywords
anti-HIV-1; bone marrow stromal cell antigen 2; Vpu; drug design
Categories
Funding
- 973 Program [2012CB911102]
- National S&T Major Special Project on Major New Drug Innovation [2012ZX09102101-018]
- Chinese National Natural Science Foundation [81271844]
Ask authors/readers for more resources
Bone marrow stromal cell antigen 2 (BST-2) inhibits the release of HIV-1 and other enveloped viruses from the cell surface. HIV-1 Vpu binds to BST-2 through an interaction between transmembrane domains (TMD) of the two proteins and induces the downregulation of cell surface BST-2, thereby counteracting its antiviral activity. In this study, we designed and prepared a modified peptide BST2-TM-P1, which include the sequence of BST-2 TMD, keeping its property competing with BST-2 to bind with Vpu. Biological assay results indicate BST2-TM-P1 could increase the BST-2 level at the cell surface in Vpu dependent manner and significantly inhibit the replication of HIV-1 virion. Our studies indicate that blocking the interaction of Vpu and BST-2 is an effective way to combat HIV-1 infection. (C) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available